Actinium Pharmaceuticals, Inc. (ATNM) vs Celularity, Inc. (CELU)

Actinium Pharmaceuticals, Inc. and Celularity, Inc. are both Biotechnology companies. Actinium Pharmaceuticals, Inc. and Celularity, Inc. are of similar size ($38.2M and $37.4M). Celularity, Inc. has negative trailing earnings, so its P/E is not meaningful; Actinium Pharmaceuticals, Inc. trades at 3.3×. Actinium Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 2,731.2% against −51.0%. Actinium Pharmaceuticals, Inc. has the higher net margin (32.2% vs −345.8%) and the higher return on invested capital (0.00% vs −1,070.9%). Across the 16 metrics below, Actinium Pharmaceuticals, Inc. leads on 11 and Celularity, Inc. on 5.

Valuation

Metric ATNM CELU Biotechnology median
P/E 3.33 n/m 7.88
P/S 1.07 1.33 11.47
P/B 1.24 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.17 n/m 0.74
EV/Sales 0.05 2.90 10.73
Earnings yield 30.00% (259.89%) (28.84%)
Free cash flow yield (61.70%) (37.97%) (23.03%)

Profitability

Metric ATNM CELU Biotechnology median
Gross margin 98.71% 24.39% 65.16%
Operating margin 27.20% (230.92%) 0.00%
Net margin 32.18% (345.76%) 0.00%
Free cash flow margin (66.16%) (49.92%) 0.00%
Return on equity 45.86% 628.23% (57.72%)
Return on assets 21.92% (76.50%) (49.22%)
Return on invested capital 0.00% (1,070.92%) 0.00%

Growth

Metric ATNM CELU Biotechnology median
Revenue growth (TTM) 2,731.18% (51.03%) 5.64%
EPS growth (last fiscal year) 14.17% (35.71%) —
Revenue growth, 5-year CAGR — 13.21% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATNM CELU Biotechnology median
Debt to equity 0.00 (1.26) 0.00
Current ratio 4.08 0.15 4.73
Net debt to EBITDA 1.35 (0.77) 0.96

Dividend

Metric ATNM CELU Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ATNM CELU Biotechnology median
Market cap 37.42m 38.21m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack